Compare Aurobindo Pharma with VIVIMED LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs VIVIMED LABS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA VIVIMED LABS AUROBINDO PHARMA/
VIVIMED LABS
 
P/E (TTM) x 6.8 -1.6 - View Chart
P/BV x 1.6 0.2 820.1% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 AUROBINDO PHARMA   VIVIMED LABS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-21
VIVIMED LABS
Mar-20
AUROBINDO PHARMA/
VIVIMED LABS
5-Yr Chart
Click to enlarge
High Rs1,02327 3,733.9%   
Low Rs3337 5,128.5%   
Sales per share (Unadj.) Rs422.8127.7 331.1%  
Earnings per share (Unadj.) Rs92.0-13.2 -698.9%  
Cash flow per share (Unadj.) Rs110.0-5.1 -2,162.5%  
Dividends per share (Unadj.) Rs4.000-  
Avg Dividend yield %0.60-  
Book value per share (Unadj.) Rs374.3100.7 371.8%  
Shares outstanding (eoy) m585.9482.91 706.7%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.60.1 1,208.5%   
Avg P/E ratio x7.4-1.3 -572.5%  
P/CF ratio (eoy) x6.2-3.3 -185.0%  
Price / Book Value ratio x1.80.2 1,076.1%  
Dividend payout %4.30-   
Avg Mkt Cap Rs m397,3981,405 28,276.7%   
No. of employees `000NANA-   
Total wages/salary Rs m35,3502,334 1,514.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m247,74610,588 2,339.9%  
Other income Rs m3,809119 3,188.4%   
Total revenues Rs m251,55510,707 2,349.3%   
Gross profit Rs m81,48066 124,339.7%  
Depreciation Rs m10,554669 1,576.5%   
Interest Rs m745610 122.1%   
Profit before tax Rs m73,990-1,095 -6,758.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m20,098-4 -558,269.4%   
Profit after tax Rs m53,892-1,091 -4,939.0%  
Gross profit margin %32.90.6 5,313.9%  
Effective tax rate %27.20.3 8,260.2%   
Net profit margin %21.8-10.3 -211.1%  
BALANCE SHEET DATA
Current assets Rs m198,2359,753 2,032.6%   
Current liabilities Rs m106,6527,704 1,384.4%   
Net working cap to sales %37.019.4 191.0%  
Current ratio x1.91.3 146.8%  
Inventory Days Days1930 64.6%  
Debtors Days Days5286 60.1%  
Net fixed assets Rs m135,77812,206 1,112.4%   
Share capital Rs m5863,418 17.1%   
"Free" reserves Rs m218,7134,928 4,438.3%   
Net worth Rs m219,2998,346 2,627.6%   
Long term debt Rs m1,6844,704 35.8%   
Total assets Rs m334,01321,959 1,521.1%  
Interest coverage x100.3-0.8 -12,637.7%   
Debt to equity ratio x00.6 1.4%  
Sales to assets ratio x0.70.5 153.8%   
Return on assets %16.4-2.2 -747.0%  
Return on equity %24.6-13.1 -188.0%  
Return on capital %33.8-3.7 -910.9%  
Exports to sales %53.87.0 764.8%   
Imports to sales %16.40-   
Exports (fob) Rs m133,248745 17,894.5%   
Imports (cif) Rs m40,615NA-   
Fx inflow Rs m133,248745 17,894.5%   
Fx outflow Rs m44,946770 5,835.4%   
Net fx Rs m88,302-26 -345,065.3%   
CASH FLOW
From Operations Rs m33,289796 4,184.2%  
From Investments Rs m5,987-1,960 -305.4%  
From Financial Activity Rs m-13,648724 -1,884.2%  
Net Cashflow Rs m25,831-440 -5,868.7%  

Share Holding

Indian Promoters % 48.8 28.6 170.7%  
Foreign collaborators % 3.1 0.0 -  
Indian inst/Mut Fund % 37.9 1.8 2,151.1%  
FIIs % 21.4 1.6 1,303.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.2 71.4 67.4%  
Shareholders   341,568 52,074 655.9%  
Pledged promoter(s) holding % 24.4 54.2 45.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SUN PHARMA    LUPIN    CIPLA    DR. REDDYS LAB    CADILA HEALTHCARE    



Today's Market

5 Reasons Why Sensex Crashed 1,546 Points Today(Closing)

Indian share markets witnessed heavy selling pressure today and ended deep in the red. The sell-off continued for the fifth straight session today with benchmark indices losing nearly 3% each.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (down 2.0% YoY). Sales on the other hand came in at Rs 57 bn (down 3.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of AUROBINDO PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 24, 2022 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - TYCHE INDUSTRIES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS